Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

25 Oct 2016 17:43

RNS Number : 4431N
GW Pharmaceuticals PLC
25 October 2016
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Julian Gangolli

2.

Reason for the notification

a.

Position/status

Director/President, US

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

 

c.

Price(s) and volume(s)

 

Price(s)

 0.1p

Volume(s)

10,608

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

 London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

301

 

ADS's issued upon conversion of 3,612 Ordinary shares

d.

Aggregated information

·Aggregated volume

·Price

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

 

American Depositary Shares

ISIN: 36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

 

Price(s)

 $120.75

Volume(s)

301

 

ADS's sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary Share and Restricted American Depositary Shares

Ordinary Shares: ISIN: GB0030544687

Restricted American Depositary shares: ISIN: US36197T1372

b.

Nature of the transaction

Conversion of Ordinary Shares into Restricted American Depositary shares (12 to 1 Conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

583

Restricted ADSs issued upon conversion of 6,996 Ordinary Shares

d.

Aggregated information

·Aggregated volume

·Price

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Christopher Tovey

2.

Reason for the notification

a.

Position/status

Director/Chief Operations Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

c.

Price(s) and volume(s)

 

Price(s)

 0.1p

Volume(s)

266,557

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

 London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

22,213

ADS's issued upon conversion of 266,556 Ordinary shares

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

American Depositary Shares

ISIN: US36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

 

Price(s)

 $120.36

Volume(s)

22,213

 

ADS's sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Geoffrey Guy

2.

Reason for the notification

a.

Position/status

Director/Chairman of the Board

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.43p

Volume(s)

206,100

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

21 October 2016

f.

Place of the transaction

 AIM, London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

 Ordinary Shares: ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.24

Volume(s)

68,900

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

AIM, London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

0.1 Pence Ordinary Shares

ISIN:GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.09

Volume(s)

125,000

 

Ordinary Shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

AIM, London

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Stephen Wright

2.

Reason for the notification

a.

Position/status

Director/Chief Medical Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares by the wife of Dr Stephen Wright

c.

Price(s) and volume(s)

 

Price(s)

 £8.10p

Volume(s)

1,556

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

 AIM, London

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFSRIILEFIR
Date   Source Headline
24th Jun 20083:16 pmRNSTotal Voting Rights
20th Jun 200812:03 pmRNSDirector/PDMR Shareholding
19th Jun 20087:00 amRNSInterim Results
5th Jun 200811:25 amRNSNotice of Results
17th Apr 20085:19 pmRNSAdditional Listing
9th Apr 20087:00 amRNSResearch Update
8th Apr 20083:29 pmRNSDirector/PDMR Shareholding
8th Apr 20087:01 amRNSResearch Update
19th Mar 20083:29 pmRNSDirector/PDMR Shareholding
18th Mar 20083:35 pmRNSResult of AGM
18th Mar 20087:00 amRNSAGM Statement
7th Mar 200811:15 amRNSDirector/PDMR Shareholding
5th Mar 20087:00 amRNSAppointment
29th Feb 20086:04 pmRNSDirector/PDMR Shareholding
11th Feb 20087:01 amRNSBIO Conference
25th Jan 20089:46 amRNSTotal Voting Rights
22nd Jan 20087:01 amRNSResearch Update
22nd Jan 20087:00 amRNSFinal Results
7th Jan 200812:55 pmRNSNotice of Results
13th Dec 20072:01 pmRNSRe Sativex
3rd Dec 20077:00 amRNSResearch Update
26th Nov 20077:00 amRNSResearch Update
16th Nov 20071:51 pmRNSDirector/PDMR Shareholding
12th Nov 20077:01 amRNSResearch Update
25th Oct 200711:24 amRNSBlocklisting Interim Review
17th Oct 20077:01 amRNSResearch Update
10th Sep 20079:29 amRNSHolding(s) in Company
30th Aug 20077:00 amRNSResearch Update
20th Aug 20072:51 pmRNSDirector/PDMR Shareholding
20th Aug 20078:58 amRNSAIM Rule 26 Disclosure
14th Aug 20077:00 amRNSTotal Voting Rights
7th Aug 20077:00 amRNSRe Sativex approval
23rd Jul 20071:46 pmRNSDirector/PDMR Shareholding
20th Jul 20077:00 amRNSRegulatory Update
9th Jul 200712:20 pmRNSNotifiable Interest in Shares
9th Jul 20077:00 amRNSResearch Collaboration
26th Jun 20072:24 pmRNSDirector/PDMR Shareholding
19th Jun 20077:01 amRNSResearch Update
19th Jun 20077:00 amRNSInterim Results
5th Jun 200710:27 amRNSNotice of Results
4th Jun 20077:00 amRNSResearch Update
18th Apr 20071:51 pmRNSDirector/PDMR Shareholding
11th Apr 200712:49 pmRNSBlocklisting Interim Review
3rd Apr 20075:25 pmRNSDirector/PDMR Shareholding
29th Mar 20071:48 pmRNSDirector/PDMR Shareholding
26th Mar 20071:22 pmRNSDirector/PDMR Shareholding
22nd Mar 20077:00 amRNSRe License Agreement
20th Mar 20074:31 pmRNSHolding(s) in Company
20th Mar 20073:24 pmRNSAGM Statement
15th Mar 20077:01 amRNSChanges to Board of Directors

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.